{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T23:49:13Z","timestamp":1781912953838,"version":"3.54.5"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.lungcan.2025.108834","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:34:28Z","timestamp":1762562068000},"page":"108834","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["MAGELLAN arms B1 and B3: Durvalumab plus chemotherapy with and without oleclumab in treatment-na\u00efve metastatic non-small-cell lung cancer"],"prefix":"10.1016","volume":"211","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5562-270X","authenticated-orcid":false,"given":"Byoung Chul","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8659-8629","authenticated-orcid":false,"given":"Chaiyut","family":"Charoentum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5124-7132","authenticated-orcid":false,"given":"Dong-Wan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1846-1027","authenticated-orcid":false,"given":"Cheng-Ta","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8080-9843","authenticated-orcid":false,"given":"Rafal","family":"Dziadziuszko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3494-8268","authenticated-orcid":false,"given":"Sarayut Lucien","family":"Geater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9426-2332","authenticated-orcid":false,"given":"Helen","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9176-8157","authenticated-orcid":false,"given":"Banafsheh","family":"Afshar-Imani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavlo","family":"Lyfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Chih-Hsin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8387-4840","authenticated-orcid":false,"given":"Sandip Pravin","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lungcan.2025.108834_b0005","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s41591-024-02808-y","article-title":"Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial","volume":"30","author":"Besse","year":"2024","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.lungcan.2025.108834_b0010","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1200\/JCO.22.00975","article-title":"Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study","volume":"41","author":"Johnson","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108834_b0015","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2025.108834_b0020","unstructured":"I. Merck & Co., Pembrolizumab Highlights of Prescribing Information, 2024. https:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf. (Accessed 24\/10\/2024 2024)."},{"key":"10.1016\/j.lungcan.2025.108834_b0025","unstructured":"AstraZeneca, Durvalumab Highlights of Prescribing Information, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761069s033lbl.pdf. (Accessed 24\/10\/2024 2024)."},{"issue":"19","key":"10.1016\/j.lungcan.2025.108834_b0030","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108834_b0035","doi-asserted-by":"crossref","first-page":"S225","DOI":"10.1016\/j.jtho.2021.01.143","article-title":"FP13.04 KEYNOTE-042 3-Year Survival Update: 1L Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ Locally Advanced\/Metastatic NSCLC","volume":"16","author":"Cho","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2025.108834_b0040","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1200\/JCO.23.02746","article-title":"Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3","volume":"42","author":"Jaiyesimi","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2025.108834_b0045","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab Plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2025.108834_b0050","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study","volume":"41","author":"Novello","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2025.108834_b0055","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.11113","article-title":"Association between first-line immune checkpoint inhibition and survival for medicare-insured patients with advanced non-small cell lung cancer","volume":"4","author":"Kehl","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.lungcan.2025.108834_b0060","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.lungcan.2021.04.007","article-title":"Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer","volume":"156","author":"Waterhouse","year":"2021","journal-title":"Lung Cancer"},{"issue":"21","key":"10.1016\/j.lungcan.2025.108834_b0065","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50","volume":"39","author":"Reck","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108834_b0070","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008189","article-title":"Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial","volume":"12","author":"Carbone","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"12","key":"10.1016\/j.lungcan.2025.108834_b0075","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s40265-017-0782-5","article-title":"Durvalumab: first global approval","volume":"77","author":"Syed","year":"2017","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.lungcan.2025.108834_b0080","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1007\/s00262-023-03430-6","article-title":"First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors","volume":"72","author":"Bendell","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"issue":"13","key":"10.1016\/j.lungcan.2025.108834_b0085","first-page":"2602","article-title":"The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine","volume":"57","author":"Blay","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108834_b0090","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3389\/fimmu.2016.00109","article-title":"A metabolic immune checkpoint: adenosine in tumor microenvironment","volume":"7","author":"Ohta","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lungcan.2025.108834_b0095","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.coph.2020.07.001","article-title":"Targeting CD73 to augment cancer immunotherapy","volume":"53","author":"Roh","year":"2020","journal-title":"Curr. Opin. Pharmacol."},{"issue":"12","key":"10.1016\/j.lungcan.2025.108834_b0100","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nrc.2017.86","article-title":"Targeting immunosuppressive adenosine in cancer","volume":"17","author":"Vijayan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"16_suppl","key":"10.1016\/j.lungcan.2025.108834_b0105","doi-asserted-by":"crossref","first-page":"8046","DOI":"10.1200\/JCO.2024.42.16_suppl.8046","article-title":"Updated results from COAST, a phase 2 study of durvalumab (D) \u00b1 oleclumab (O) or monalizumab (M) in patients (pts) with stage III unresectable non-small cell lung cancer (uNSCLC)","volume":"42","author":"Aggarwal","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108834_b0110","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s12672-025-02179-x","article-title":"Quantifying CD73 expression after chemotherapy or chemoradiotherapy in esophageal squamous cell carcinoma","volume":"16","author":"Cooper","year":"2025","journal-title":"Discov. Oncol."},{"issue":"29","key":"10.1016\/j.lungcan.2025.108834_b0115","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.22.00227","article-title":"COAST: an open-label, phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage III non-small-cell lung cancer","volume":"40","author":"Herbst","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"4_Supplement","key":"10.1016\/j.lungcan.2025.108834_b0120","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS21-PD10-03","article-title":"Abstract PD10-03: BEGONIA: phase 1b\/2 study of durvalumab (D) combinations in locally advanced\/metastatic triple-negative breast cancer (TNBC): results from arm 1 D + paclitaxel (P), arm 2 D+P + capivasertib (C), and arm 5 D+P + oleclumab (O)","volume":"82","author":"Schmid","year":"2022","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108834_b0125","doi-asserted-by":"crossref","first-page":"7018","DOI":"10.1038\/s41467-023-42744-y","article-title":"Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I\/II trial","volume":"14","author":"Buisseret","year":"2023","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.lungcan.2025.108834_b0130","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/s41416-024-02796-3","article-title":"COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer","volume":"131","author":"Segal","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"20","key":"10.1016\/j.lungcan.2025.108834_b0135","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1158\/1078-0432.CCR-24-0499","article-title":"A phase Ib\/II randomized clinical trial of oleclumab with or without durvalumab plus chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma","volume":"30","author":"Coveler","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.lungcan.2025.108834_b0140","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1158\/2159-8290.CD-23-0436","article-title":"Neoadjuvant durvalumab alone or combined with novel immuno-oncology agents in resectable lung cancer: the phase II NeoCOAST platform trial","volume":"13","author":"Cascone","year":"2023","journal-title":"Cancer Discov."},{"issue":"29","key":"10.1016\/j.lungcan.2025.108834_b0145","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1080\/14796694.2024.2354160","article-title":"PACIFIC-9: phase III trial of durvalumab+oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer","volume":"20","author":"Barlesi","year":"2024","journal-title":"Future Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225007263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225007263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T01:03:18Z","timestamp":1773882198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225007263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":29,"alternative-id":["S0169500225007263"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108834","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MAGELLAN arms B1 and B3: Durvalumab plus chemotherapy with and without oleclumab in treatment-na\u00efve metastatic non-small-cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108834","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108834"}}